That’s great. It’s hard to be an investor in a biotech without being able to compare two companies and their relative strengths.
RGS sounds positive and I may get in at some point. Thanks for the insights.
Ann: Kyocera completes Progenza Due Diligence, page-9
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.579M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6637 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 4968 | 2 |
View Market Depth
| Last trade - 16.12pm 13/09/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable